

CURRICULUM VITAE

Fritz Sieber PhD

Professor
Department of Pediatrics
Division of Hematology and Oncology - Pediatrics

OFFICE ADDRESS:

MACC Fund Research Center
8701 Watertown Plank Rd
Milwaukee, WI 53226

EDUCATION:

1966 - Present Matura, Kantonsschule Zug
1971 - Present Dipl Natw ETH (MS), Swiss Federal Institute of Technology, Zürich.
1976 - Present Dr sc nat ETH (PhD), Swiss Federal Institute of Technology, Zürich.

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

1976 - 1979 Swiss National Science Foundation Fellow, Department of Biology, The Johns Hopkins University, Baltimore, MD

MILITARY SERVICE:

1966 - 1976 Swiss Army, Field Artillery, Gunner, Corporal, 2nd Lieutenant, 1st Lieutenant

FACULTY APPOINTMENTS:

1979 - 1985 Assistant Professor of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD
1980 - 1985 Assistant Professor of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD
1985 - 1990 Associate Professor of Pediatrics (Hematology/Oncology), Medical College of Wisconsin, Milwaukee, WI
1986 - Present Joint appointments in Department of Cell Biology, Neurobiology & Anatomy, Department of Microbiology & Molecular Genetics, WI
1990 - 1992 Professor of Pediatrics (Hematology/Oncology), Medical College of Wisconsin, Milwaukee, WI
1992 - Present Professor of Pediatrics & Medicine (Cancer and Blood Diseases) with Tenure, Medical College of Wisconsin, Milwaukee, WI

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:

1987 - Present Doctoral Staff, Children's Hospital of Wisconsin, Milwaukee, WI
2010 - Present Chair, Steering Committee, Postdoctoral Training Program, Children's Research Institute, WI

AWARDS AND HONORS:

1966 - Present Willy Beusch-Prize, Zug
1976 - Present Swiss National Science Foundation Fellowship
1977 - Present Swiss National Science Foundation Fellowship
1978 - Present Scholarship for Advanced Young Scientists from Swiss National Science Foundation
1980 - Present Hubert E and Anne E Rogers Award
1984 - Present Leukemia Society of America Scholar
1987 - Present Frederick Stohlman Memorial Award of the Leukemia Society of America
1991 - Present 20th Annual Meeting of the International Society for Experimental Hematology, Parma, Italy, July 21-25. Paper recognized as "Most Cited Experimental Hematology Article"

1998 - Present 27th Annual Meeting of the International Society for Experimental Hematology, Vancouver, Canada, August 1-5. Two papers recognized as "Top 30 (top 2%) Publications Published in Experimental Hematology Between 1990 and 1998"

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

1974 - Present Union of Swiss Societies of Experimental Biology
1974 - Present New York Academy of Sciences
1975 - Present International Society for Differentiation
1978 - Present American Association for the Advancement of Science
1978 - Present American Society for Cell Biology
1979 - Present International Society for Experimental Hematology
1980 - Present International Society of Developmental Biologists
1980 - Present Society of General Physiologist
1981 - Present American Society of Hematology
1982 - Present Society for Analytical Cytology
1982 - Present American Federation for Clinical Research
1982 - Present International Society for Experimental Hematology Member, Organizing Committee (Annual Meeting)
1982 - Present International Society for Experimental Hematology Session Chairman
1983 - Present American Society of Hematology Session Chairman
1983 - Present International Association for Comparative Research on Leukemia and Related Diseases
1985 - Present American Society for Photobiology
1986 - Present Pediatric Oncology Group/Children's Oncology Group
1987 - Present American Association for Cancer Research
1990 - Present International Photodynamic Association
1991 - Present International Society for Experimental Hematology Co-organizer and co-chairman (Satellite Symposium on Photobiology and Photomedicine)
1993 - Present International Society for Hematotherapy & Graft Engineering
1994 - Present American Society for Photobiology Session Chairman
1997 - Present American Society for Photobiology Symposium Organizer
1997 - Present American Chemical Society
2007 - Present International Photodynamic Association Scientific Committee (11th World Congress)
2007 - Present International Photodynamic Association Session Chair (11th World Congress)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:

Editorship

1987 - 1992 Cancer Therapy and Control
1997 - 2002 Cancer Research, Therapy & Control

Editorial Board

1992 - 2002 Cancer Research, Therapy & Control
2006 - Present Chemical Biology

Journal Review

1985 - Present Journal of Photochemistry & Photobiology
1985 - Present International Immunopharmacology
1985 - Present Technology in Cancer Research and Treatment
1985 - Present Acta Pharmacologica Sinica
1985 - Present Blood
1985 - Present Cancer Research
1985 - Present Experimental Hematology
1985 - Present Bone Marrow Transplantation
1985 - Present Photochemistry and Photobiology
1985 - Present Transfusion
1985 - Present Proceedings of the National Academy of Sciences USA
1985 - Present British Journal of Cancer
1985 - Present Transplantation
1985 - Present Leukemia Research, Biochimica et Biophysica Acta
1985 - Present Radiation and Environmental Biophysics

1985 - Present Laboratory Investigation
1985 - Present International Journal of Radiation Biology
1985 - Present Archives of Biochemistry and Biophysics
1985 - Present Clinical Cancer Research
1985 - Present International Journal of Cancer
1985 - Present Cancer Detection and Prevention
1985 - Present Anatomical Record
1985 - Present Biology of Blood and Marrow Transplantation
1985 - Present Free Radical Biology and Medicine
1985 - Present Molecular Cancer Therapeutics

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

Member, Peer Review Committee, American Heart Association-Wisconsin Affiliate
Board member and chairman Special Gifts Committee, American Cancer Society-Milwaukee

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

1985 - 1988 Ad hoc member, Experimental Therapeutics Study Section, NIH
1985 - 1986 Ad hoc reviewer, Veterans Administration
1987 Member, Organizing Committee, Leukemia Society of America 4th Annual Meeting
1990 Ad hoc reviewer, American Red Cross
1992 Ad hoc reviewer, Alberta Heritage Foundation for Medical Research
1994 Member, Special Emphasis Review Panel, National Heart, Lung, and Blood Institute
1994 Organizer, Symposium "Advances in Photodynamic Therapy and the Fluorescence Detection of Small Tumors"
1995 Experimental Therapeutics-1 Study Section, NIH
1996 Ad hoc reviewer, Veterans Administration
1997 Ad hoc reviewer, Medical Research Council of Canada
1998 Ad hoc reviewer, Hematology Study Section, NIH
2000 Member, Special Emphasis Review Panel, Experimental Therapeutics-2 Study Section, NIH

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

Local

Symposium "Advances in Photodynamic Therapy and the Fluorescence Detection of Small Tumors",
Children' Hospital of Wisconsin, Milwaukee, WI, 09/19/1994 - Present
Symposium CENTRII 2009, Center for Medical Countermeasures Against Radiological Terrorism,
Milwaukee, WI, 04/01/2009 - Present
Nephrology Section, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, 04/20/2010 -
Present

Regional

The Upjohn Company, Kalamazoo, MI, 03/06/1985 - Present
Wisconsin Dermatological Society, 10/11/1986 - Present
Leukemia Society of America-Wisconsin, 06/15/1988 - Present
Wayne State University, Detroit, MI, 03/20/1989 - Present
Therapeutic Immunology Inc, Minneapolis, MN, 03/26/1990 - Present
Symposium on Photochemical Blood Sterilization, 21st Annual Meeting of the American Society for
Photobiology, Chicago, IL, 06/29/1993 - Present
Fourth Great Lakes PDT Conference, Detroit, MI, 05/06/1995 - Present
University of Wisconsin-Madison, School of Pharmacy, Madison, WI, 10/24/1997 - Present
University of Wisconsin-Madison, School of Engineering, Wisconsin Center for Space Automation and
Robotics, Madison, WI, 02/12/1998 - Present

National

Upstate Medical Center, Syracuse, NY, 02/12/1985 - Present
Memorial Sloan-Kettering Cancer Center, New York, NY, 01/14/1986 - Present
Developmental and Clinical Investigation Program, Sloan-Kettering Institute, New York, NY, 02/13/1986 -
Present

Eastman-Kodak Company, Rochester, NY, 07/07/1986 - Present
First International Workshop on Bone Marrow Purging, Orlando, FL, 02/13/1987 - Present
Photodynamic Therapy Conference, Marina del Rey, CA, 02/17/1987 - Present
The New York Blood Center, New York, NY, 03/05/1987 - Present
Third National Leukemia Society of America Symposium, San Diego, CA, 03/19/1987 - Present
St. Jude Children's Research Hospital, Memphis, TN, 10/09/1987 - Present
Conference on New Directions in Photodynamic Therapy, Cambridge, MA, 10/29/1987 - Present
Eastman Pharmaceuticals, Great Valley, PA, 04/06/1988 - Present
Sterling Research Group, Malvern, PA, 07/20/1988 - Present
4th International Symposium on Autologous Bone Marrow Transplantation, Houston, TX, 08/20/1988 - Present
Advances in Photochemotherapy, Boston, MA, 09/07/1988 - Present
Sterling Research Group, Malvern, PA, 10/27/1988 - Present
31st Annual Meeting, American Society of Hematology, Atlanta, GA, 12/05/1988 - Present
SPIE Think Tank on the Future of Photodynamic Therapy, San Diego, CA, 01/20/1990 - Present
The James Graham Brown Cancer Center, University of Louisville, Louisville, KY, 10/04/1990 - Present
Symposium on the Photoinactivation of Viruses and Cells for Medical Applications, 19th Annual Meeting of the American Society for Photobiology, San Antonio, TX, 06/24/1991 - Present
6th Annual Meeting of the Clinical Immunology Society, Arlington, VA, 11/02/1991 - Present
Symposium on DNA Cleavage and Viral Inactivation, American Chemical Society Regional Meeting, Cincinnati, OH, 05/27/1992 - Present
Symposium on the Sterilization of Blood by Light, 20th Annual Meeting of the American Society for Photobiology, Marco Island, FL, 06/24/1992 - Present
4th International on Bone Marrow Purging and Processing, Orlando, FL, 09/17/1993 - Present
The Temple University Cancer Center, Philadelphia, PA, 02/10/1994 - Present
Space Technology and Applications International Forum, Albuquerque, NM, 01/11/1996 - Present
Workshop "Photopheresis: Paradigms and Mechanisms", 25th Annual Meeting of the American Society for Photobiology, St. Louis, MO, 07/05/1997 - Present
Symposium "New Developments in Extracorporeal Photochemotherapy" 25th Annual Meeting of the American Society for Photobiology, St. Louis, MO, 07/09/1997 - Present
National Cancer Institute, Rockville, MD, 08/12/2003 - Present
Photonics West, BiOS 2005, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy. San Jose, CA, 01/22/2005 - Present

International

Autologous Bone Marrow Transplant Meeting, Parma, Italy, 07/09/1985 - Present
Second International Symposium on Detection and Treatment of Minimal Residual Disease in Leukemia, Rotterdam, The Netherlands, 11/07/1985 - Present
Quadra Logic Technologies and University of British Columbia, Vancouver, BC, Canada, 01/05/1989 - Present
18th Annual Meeting, International Society for Experimental Hematology, Paris, France, 07/20/1989 - Present
Annual Meeting, American Society for Photobiology, Vancouver, BC, 06/20/1990 - Present
Photodynamic Therapy Workshop, University of British Columbia, Vancouver, BC, 06/21/1990 - Present
Satellite Symposium on Photobiology and Photomedicine, 20th Annual Meeting of the International Society for Experimental Hematology, Parma, Italy, 07/27/1991 - Present
4th Congress of the European Society for Photobiology, Amsterdam, The Netherlands, 09/03/1991 - Present
11th International Congress on Photobiology, Kyoto, Japan, 09/10/1992 - Present
Theratechnologies, Inc. and McGill University, Montreal, Canada, 06/22/1998 - Present
Immunotech SA, Marseille, France, 07/15/1999 - Present
Inaugural Plenary Lecture, 9th International Conference on the Chemistry of Selenium and Tellurium (ICCST-9), Bombay, India, 02/24/2004 - Present
11th World Congress of the International Photodynamic Association. Shanghai, China, 03/31/2007 - Present

COMMITTEE SERVICE:

Medical College of Wisconsin

Photobiology/Photomedicine Committee (chair)
Computer Committee, Department of Pediatrics
Cancer Center Working Group on Photodynamic Therapy (chair)
Incentive Plan Task Force, Department of Pediatrics
Pediatrics Research Committee, Department of Pediatrics (chair)
Computer Task Force, Department of Pediatrics (chair)
Web Committee, Dept. Pediatrics
Nominations Committee, Graduate School of Biomedical Sciences
Grant reviewer for MCW Research Affairs Committee, MCW Cancer Center and Advancing a Healthier Wisconsin Program
Faculty Development Committee, Department of Medicine
Space and Equipment Committee, Department of Pediatrics
Immunology Search Committee, MCW Cancer Center
Immunology Search Committee, Department of Microbiology
PhD Thesis Committee of Gary J Bachowski
PhD Thesis Committee of James P Thomas
PhD Thesis Committee of David K Gaffney (MSTP Student)
Graduate Division Faculty Credentials Committee
Medical Scientist Training Program

Hospital

1985 - 1992 Ad hoc reviewer, Research and Publications Committee/Human Rights Review Board, Children's Hospital of Wisconsin
1992 - 2002 Member, Funding Subcommittee, Research and Publications Committee/Human Rights Review Board of Children's Hospital of Wisconsin
1992 - Present Member, IRB 2, Children's Hospital of Wisconsin
1994 - 1998 Member, Peer Review Committee, Children's Hospital Foundation
2000 - 2002 Ad hoc reviewer, Children's Hospital Foundation
2000 - 2002 Chair, Funding Subcommittee, Research and Publications Committee/ Human Rights Review Board of Children's Hospital of Wisconsin
2009 - Present Chair, Steering Committee, CRI Postdoctoral Training Program

MEDICAL COLLEGE TEACHING ACTIVITIES:

Medical Student Education

First year medical students: Histology
First year medical students: Cell and Tissue Biology
Interdisciplinary Neuroscience Program: Laboratory Research
Biochemistry 295: Readings and Research
Second year medical students: Microbiology

Graduate Student Education

Anatomy 250: Advanced Cell Biology

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. **Sieber F**, Fox DJ and Ursprung H: Properties of octanoldehydrogenase from Drosophila. FEBS Letters 26:274-276, 1972.
2. Madhavan K, Conscience-Egli M, **Sieber F** and Ursprung H: Farnesol metabolism in Drosophila melanogaster: ontogeny and tissue distribution of octanoldehydrogenase and aldehyde oxidase. J Insect Physiol 19:235-241, 1973.
3. Iscove NN, **Sieber F** and Winterhalter KH: Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin-A. J Cell Physiol 83:309-320, 1974.
4. Iscove NN and **Sieber F**: Erythroid progenitors in mouse bone marrow detected by macroscopic colony

- formation in culture. *Exp Hematol* 3:32-43, 1975.
5. **Sieber F**: Chromatography of human urinary erythropoietin and granulocyte colony stimulating factor on insolubilized phytohaemagglutinin. *Biochim Bio-phys Acta* 496:146-154, 1977.
 6. Sieber-Blum M, **Sieber F** and Yamada KM: Cellular fibronectin promotes development of quail neural crest cells in vitro. *Exp Cell Res* 133:285-295, 1981.
 7. **Sieber F**, Meagher RC and Spivak JL: Differential sensitivity of mouse hematopoietic stem cells to merocyanine 540. *Differentiation* 19:65-67, 1981.
 8. **Sieber F** and Roseman S: Quantitative analysis of intercellular adhesive specificity in freshly explanted and cultured cells. *J Cell Biol* 90:55-62, 1981.
 9. **Sieber F**, Stuart RK and Spivak JL: Tumor-promoting phorbol esters stimulate myelopoiesis and suppress erythropoiesis in cultures of mouse bone marrow cells. *Proc Natl Acad Sci USA* 78:4402-4406, 1981.
 10. Sieber-Blum M and **Sieber F**: Tumor-promoting phorbol esters promote melanogenesis and prevent expression of the adrenergic phenotype in quail neural crest cells. *Differentiation* 20:117-123, 1981.
 11. Kuhlenschmidt MS, Schmell E, Slife CW, Kuhlenschmidt TB, **Sieber F**, Lee, YC and Roseman S: Studies on the intercellular adhesion of rat and chicken hepatocytes: conditions affecting cell-cell specificity. *J Biol Chem* 257:3157-3164, 1982.
 12. **Sieber F** and Sharkis SJ: Modulation of murine erythropoiesis in vitro by syngeneic thymocytes: interactions of enhancing and suppressing subpopulations with fluorescent anti-theta antibody and polyamino acids. *Blood* 60:845-849, 1982.
 13. Meagher RC, **Sieber F** and Spivak JL: Suppression of hematopoietic progenitor cell proliferation by ethanol and acetaldehyde. *N Engl J Med* 307:845-849, 1982.
 14. Dover GJ, Chan T and **Sieber F**: Fetal Hemoglobin production in cultures of primitive and mature human erythroid progenitors. Differentiation affects the quantity of fetal hemoglobin produced per cell not the number of fetal hemoglobin-containing cells. *Blood* 61:1242-1246, 1983.
 15. Meagher RC, **Sieber F** and Spivak JL: Susceptibility to merocyanine 540-mediated photosensitization: a differentiation marker on murine hematopoietic progenitor cells. *J Cell Physiol* 116:118-124, 1983.
 16. LaRussa VF, **Sieber F**, Sensenbrenner LL and Sharkis SJ: Effects of neuraminidase on the regulation of erythropoiesis. *Blood* 63:784-788, 1984.
 17. Sieber-Blum M. and **Sieber F**.: Heterogeneity among early quail neural crest cells. *Develop Brain Res* 14:241-246, 1984.
 18. **Sieber F**, Spivak JL and Sutcliffe AM: Selective killing of leukemic cells by merocyanine 540-mediated photosensitization. *Proc Natl Acad Sci USA* 81:7584-7587, 1984.
 19. **Sieber F** and Sieber-Blum M: Dye-mediated photosensitization of murine neuroblastoma cells. *Cancer Res* 46:2072-2076, 1986.
 20. **Sieber F**, Rao S, Rowley SD and Sieber-Blum M: Dye-mediated photolysis of human neuroblastoma cells: Implications for autologous bone marrow transplantation. *Blood* 68:32-36, 1986.
 21. Levine RF, Spivak JL, Meagher RC and **Sieber F**: Effect of ethanol on thrombopoiesis. *Br J Haematol* 62:345-354, 1986.
 22. **Sieber F**, Stuart RK, Rowley SD, Sharkis SJ and Sensenbrenner LL: Dye-mediated photolysis of normal and neoplastic hematopoietic cells. *Leukemia Res* 11:43-49, 1987.
 23. **Sieber F**.: Elimination of residual tumor cells from autologous bone marrow grafts by dye-mediated photolysis: preclinical data. *Photochem Photobiol* 46:71-76, 1987.
 24. Kalyanaraman B, Feix JB, **Sieber F**, Thomas JP and Girotti AW: Photodynamic action of merocyanine 540 on artificial and natural cell membranes: Involvement of singlet molecular oxygen. *Proc Natl Acad Sci USA* 84:2999-3003, 1987.
 25. **Sieber F**, O'Brien JM, Krueger GJ, Schober SL, Burns WH, Sharkis SJ and Sensenbrenner LL: Antiviral activity of merocyanine 540. *Photochem Photobiol* 46:707-711, 1987.
 26. **Sieber F**, Krueger GJ, O'Brien JM, Schober SL, Sensenbrenner LL and Sharkis SJ: Inactivation of Friend erythroleukemia virus and Friend virus-transformed cells by merocyanine 540-mediated photosensitization. *Blood* 73:345-350, 1989.
 27. O'Brien JM and **Sieber F**: Mutagenicity of merocyanine 540-mediated photosensitization. *Exp Hematol* 17:166-170, 1989.
 28. **Sieber F** and Krueger GJ: Photodynamic therapy and bone marrow transplantation. *Sem Hematol* 26:35-39, 1989.
 29. Gaffney DK, Schober SL and **Sieber F**: Merocyanine 540-sensitized photoinactivation of leukemia cells: Role of oxygen and effects on plasma membrane integrity and mitochondrial respiration. *Exp Hematol*

- 18:23-26, 1990.
30. Smith OM and **Sieber F**: Antineoplastic and virucidal effects of merocyanine 540. *Trends in Photochemistry & Photobiology* 1:49-59, 1990.
 31. O'Brien JM, Montgomery RR, Burns WH, Gaffney DK and **Sieber F**: Evaluation of merocyanine 540-sensitized photoirradiation as a means to inactivate enveloped viruses in blood products. *J Lab Clin Med* 116:439-447, 1990.
 32. Gaffney DK and **Sieber F**: Merocyanine 540-sensitized photoinactivation of soluble and membrane-bound enzymes in L1210 leukemia cells. *Cancer Res* 50:7765-7769, 1990.
 33. Gaffney DK, O'Brien JM and **Sieber F**: Modulation by thiols of the merocyanine 540-sensitized photolysis of leukemia cells, red cells, and herpes simplex virus type 1. *Photochem Photobiol* 53:85-92, 1991.
 34. Smith OM, Traul DL, McOlash L and **Sieber F**: Evaluation of merocyanine 540-sensitized photoirradiation as a method for purging malarially-infected red cells from blood. *J Infect Diseases* 163:1312-1317, 1991.
 35. Lum LG, Yamagami M, Giddings BR, Joshi I, Schober SL, Sensenbrenner LL and **Sieber F**: The immunoregulatory effects of merocyanine 540 on in vitro human T and B lymphocyte functions. *Blood* 77:2701-2706, 1991.
 36. Smith OM, Gaffney DK, Anderson MS, McOlash L, Schober SL and **Sieber F**: Plasma membrane properties regulating the sensitivity of leukemia, lymphoma, and solid tumor cells to merocyanine 540-sensitized photoirradiation. *Exp Hematol* 19:785-788, 1991.
 37. Gaffney DK, Feix JB, Schwarz HP, Struve MF and **Sieber F**: Cholesterol content but not plasma membrane fluidity influences the susceptibility of L1210 leukemia cells to merocyanine 540-sensitized irradiation. *Photochem Photobiol* 54:717-723, 1991.
 38. O'Brien JM, Singh RJ, Feix JB, Kalyanaraman B and **Sieber F**: Action spectra of the antileukemic and antiviral activities of merocyanine 540. *Photochem Photobiol* 54:851-854, 1991.
 39. Itoh T, Gaffney DK, and **Sieber F**: Merocyanine 540 as a marrow purging agent: Split addition of dye in two half-doses reduces toxicity to normal hematopoietic stem cells without reducing the antineoplastic effect. *Cancer Ther Contr* 2:251-258, 1992.
 40. Whelan HT, Traul DL, Przybylski C, Segura A, Thomas J, Meyer G and **Sieber F**: Interactions of merocyanine 540 with human brain tumor cells. *Ped Neurol* 8:117-120, 1992.
 41. Qiu K, Traul DL and **Sieber F**: Limited cell-cycle dependence of the merocyanine 540-sensitized photoinactivation of L1210 leukemia cells. *Photochem Photobiol* 56:277-280, 1992.
 42. Qiu K and **Sieber F**: Merocyanine 540-sensitized photoinactivation of leukemia cells: Effects of dose fractionation. *Photochem Photobiol* 56:489-493, 1992.
 43. O'Brien JM, Gaffney DK, Wang TP and **Sieber F**: Merocyanine 540-sensitized photoinactivation of enveloped viruses in blood products: Site and mechanism of phototoxicity. *Blood* 80:277-285, 1992.
 44. Smith OM, Dolan SA, Dvorak JA, Wellems TE and **Sieber F**: Merocyanine 540-sensitized photoinactivation of human erythrocytes parasitized by *Plasmodium falciparum*. *Blood* 80:21-24, 1992.
 45. Smith OM, Traul DL and **Sieber F**: Photodamaging effects of merocyanine 540 on neutrophils and HL-60 cells. *Exp Hematol* 20:1278-1284, 1992.
 46. Gaffney DK and **Sieber F**: The role of serum and serum components in the merocyanine 540-sensitized photoinactivation of K562 leukemia cells. *Biochim Bio-phys Acta* 1117:321-325, 1992.
 47. Smith OM, Qiu K, Witt PL, Borden EC and **Sieber F**: Merocyanine 540 and two-phase partitioning detect interferon- β -induced plasma membrane alterations in Daudi lymphoma cells. *Cancer Res Ther Contr* 3:87-93, 1993.
 48. Qiu K and **Sieber F**: Pharmacokinetics of merocyanine 540. *Cancer Res Ther Contr* 3:239-243, 1993.
 49. Itoh T, Messner HA, Jamal N, Tweeddale M and **Sieber F**: Merocyanine 540-sensitized photoinactivation of high-grade non-Hodgkin's lymphoma cells: Potential application in autologous bone marrow transplantation. *Bone Marrow Transpl* 12:191-196, 1993.
 50. Krieg M, Bilitz JM, Traul DL and **Sieber F**: Photosensitizing oxonol dyes with antineoplastic activity. *Cancer Res Ther Contr* 4:163-172, 1995.
 51. Traul DL, Anderson GS, Bilitz JM, Krieg M and **Sieber F**: Potentiation of Merocyanine 540-mediated photodynamic therapy by salicylate and related drugs. *Photochem Photobiol* 62:790-799, 1995.
 52. Anderson GS, Günther WHH, Searle R, Bilitz JM, Krieg M and **Sieber F**: Inactivation of photosensitizing merocyanine dyes by plasma, serum, and serum components. *Photochem Photobiol* 64:683-687, 1996.
 53. Yamazaki T and **Sieber F**: The alkyl-lysophospholipid, ET-18-OCH₃ synergistically enhances the

- Merocyanine 540-mediated photoinactivation of leukemia cells: Implications for the extracorporeal purging of autologous hematopoietic stem cells. *Bone Marrow Transpl* 19:113-119, 1997.
54. Yamazaki T and **Sieber F**: Effect of hypothermia on the Merocyanine 540-mediated purging of hematopoietic cells. *J Hematother* 6:31-39, 1997.
 55. Yamazaki T, Sato Y and **Sieber F**: Role of cytoprotective mechanisms in the photochemical purging of autologous bone marrow grafts. *Exp Hematol* 25:629-637, 1997.
 56. Kubo Y and **Sieber F**: Photochemical purging of autologous bone marrow grafts: Assessment of damage to stem cells and the microenvironment in long-term marrow cultures. *Bone Marrow Transpl* 20:27-31, 1997.
 57. Sato Y, Daziano J-P and **Sieber F**: Photochemical purging of autologous stem cell grafts: Potentiation of the antileukemic activity of Merocyanine 540 by ethacrynic acid. *Cancer Res Ther Contr* 5:241-251, 1998.
 58. Indig GL, Anderson GS, Nichols MG, Barlett JA, Mellon WS and **Sieber F**: Effect of molecular structure on the performance of triarylmethane dyes as therapeutic agents for photochemical purging of autologous bone marrow grafts from residual tumor cells. *J Pharm Sci* 89:88-99, 2000.
 59. Tsujino I and **Sieber F**: Genetic variability in the response of normal murine hematopoietic progenitor cells to extracorporeal photochemotherapy. *Photochem Photobiol* 72:810-814, 2000.
 60. Tsujino I, Anderson GS and **Sieber F**: Post-irradiation hyperthermia selectively potentiates the Merocyanine 540-sensitized photoinactivation of small cell lung cancer cells. *Photochem Photobiol* 73:191-198, 2001.
 61. Anderson GS, Miyagi K, Sampson RW and **Sieber F**: Anti-tumor effect of Merocyanine 540-mediated photochemotherapy combined with Edelfosine: Potential implications for the ex vivo purging of hematopoietic stem cell grafts from breast cancer patients. *J Photochem Photobiol B: Biology* 68:101-108, 2002.
 62. Anderson GS, Tsujino I, Miyagi K, Sampson RW and **Sieber F**: Preferential inactivation of paediatric solid tumour cells by sequential exposure to Merocyanine 540-mediated photodynamic therapy and Edelfosine: Implications for the ex vivo purging of autologous haematopoietic stem cell grafts. *J Photochem Photobiol B: Biology* 69:87-95, 2003.
 63. Miyagi K, Sampson RW, Sieber-Blum M and **Sieber F**: Crystal violet and Merocyanine 540 for the ex vivo purging of hematopoietic stem cell grafts. *J Photo-chem Photobiol B: Biology* 70:133-144, 2003.
 64. Tsujino I, Miyagi K, Sampson RW and **Sieber F**: Potentiation of the anti-tumor effect of Merocyanine 540-mediated photodynamic therapy by amifostine and amphotericin B. *Photochem Photobiol*, 82:458-465, 2006.
 65. Sieber, Muir SA, Cohen EP, North PE, Fish BL, Irving AA, Mäder M and Moulder JE: High-dose selenium for the mitigation of radiation injury: a pilot study in a rat model. *Radiat Res* 171:368-373, 2009.
 66. Cunderlikova B, Vasovic V, **Sieber F**, Furre T, Nesland JM, Peng Q: Hexaminolevulinate-mediated photodynamic purging of leukemia cells from BM. *Bone Mar-row Transpl*, 45:1553-1561, 2010.
 67. Cunderlikova B, Vasovic V, **Sieber F**, Furre T, Borgen E, Nesland JM, Peng Q: Hexaminolevulinate-mediated photodynamic purging of marrow grafts with murine breast cancer carcinoma. *Bone Marrow Transpl* 46:1118-1127, 2011.
 68. **Sieber F**, Muir SA, Cohen EP, Fish BL, Mäder M, Schock AM, Althouse BJ, Moulder JE: Dietary selenium for the mitigation of radiation injury: effects of selenium dose escalation and timing of supplementation. *Radiat Res* 176: 366-374, 2011.

Books, Chapters, and Reviews

1. Iscove NN, **Sieber F** and Winterhalter K: Human urinary erythroid colony stimulating activity: assay in cultures of mouse and human bone marrow and similarity to erythropoietin on Sephadex and Concanavalin-A Sepharose. In *Hemopoiesis in Culture*. WA Robinson, ed. US Government Printing Office, Washington, pp 44-52, 1974.
2. Iscove NN, **Sieber F** and Winterhalter KH: Human urinary erythroid colony stimulating activity (E-CSA): techniques for detection in culture and chemical separations. In *Hemopoiesis in Culture*. WA Robinson, ed. US Government Printing Office, Washington, pp 421-423, 1974.
3. **Sieber F**: Erythroid colony growth in culture: effect of desialated erythropoietin, neuraminidase, dimethyl sulfoxide, and Amphotericin B. In *Progress in Differentiation Research*. N Muller-Béat, ed. North Holland, Amsterdam, pp 521-528, 1976.
4. **Sieber F**: Cell-cell interactions. In *Advanced Cell Biology*. LM Schwartz and MM Azar, eds. Van Nostrand Reinhold, New York, pp 226-233, 1981.
5. **Sieber F**, Meagher RC and Spivak JL: Susceptibility to merocyanine 540-mediated photosensitization as a

- differentiation marker in murine hematopoietic stem cells. In *Embryonic Development, Part B: Cellular Aspects*. MM Burger and R Weber, eds. Alan R Liss, New York, pp 135-144, 1982.
6. Spivak J. and **Sieber F**: Erythropoietin. In *Hormones in Normal and Abnormal Human Tissues*. K Fotherby and SB Pal, eds. DeGruyter, New York, pp 63-96, 1983.
 7. **Sieber F**, Meagher RC, Sutcliffe AM and Spivak JL: Purging of leukemic cells from bone marrow grafts by merocyanine 540-mediated photosensitization. In *Leukemia Reviews International, Vol. 1, Advances in Comparative Leukemia Re-search*. MA Rich and DS Yohn, eds. Marcel Dekker, New York and Basel, pp 30-31, 1983.
 8. **Sieber F**: Merocyanine 540-mediated photosensitization of leukemia and solid tumor cells. In *Molecular Basis of Cancer, Part B: Macromolecular Recognition, Chemotherapy, and Immunology*. R Rein, ed. Alan R Liss, New York, pp 227-234, 1985.
 9. Sieber-Blum M and **Sieber F**: In vitro analysis of quail neural crest cell differentiation. In *Cell Culture in the Neurosciences*. JE Bottenstein and G Sato, eds. Plenum, New York, pp 193-222, 1985.
 10. **Sieber F**: Detection and selective destruction of tumor cells by the lipophilic dye, merocyanine 540. In *Minimal Residual Disease in Acute Leukemia*. A Hagenbeek and B Lowenberg, eds. Martinus Nijhoff, Boston, pp 282-294, 1986.
 11. **Sieber F**: Dye-mediated photolysis of tumor cells: Implications for autologous bone marrow transplantation. In *Progress in Bone Marrow Transplantation*. RP Gale and R Champlin, eds. Alan R Liss, New York, pp 865-869, 1987.
 12. **Sieber F**: Marrow purging by merocyanine 540-mediated photolysis. *Bone Marrow Transpl* 2:29-33, 1987.
 13. **Sieber F**: Autologous bone marrow transplantation in the treatment of leukemia: Cleansing of the marrow graft. *Intern Med for the Specialist* 8:138-149, 1987.
 14. **Sieber F**: Merocyanine 540 (yearly review). *Photochem Photobiol* 46:1035-1042, 1987.
 15. **Sieber F**: A role for photodynamic therapy in autologous bone marrow transplantation. In *Proceedings of SPIE-The International Society of Optical Engineering, Vol 847, New Directions in Photodynamic Therapy*. DC Neckers, ed. SPIE, Bellingham, pp 148-152, 1987.
 16. Itoh T, Ball ED and **Sieber F**: Antileukemic effect of merocyanine 540-mediated photosensitization combined with complement-mediated immune lysis and its role in the purging of autologous remission marrow grafts. In *Bone Marrow Transplantation: Current Controversies*. RP Gale and R Champlin, eds. Alan R Liss, New York, pp 301-312, 1989.
 17. **Sieber F**: Antineoplastic and antiviral properties of merocyanine 540. In *Proceedings of SPIE-The International Society of Optical Engineering, Vol 997, Advances in Photochemotherapy*. T Hasan, ed. SPIE Optical Engineering Press, Bellingham, pp 128-131, 1989.
 18. **Sieber F**: Merocyanine 540 as a marrow purging agent: Interactions of Merocyanine 540 with normal and neoplastic cells. In *Autologous Bone Marrow Transplantation, Proceedings of the Fourth International Symposium*. KA Dicke, G Spitzer, S Jagannath and MJ Evinger-Hodges, eds. The University of Texas MD Anderson Cancer Center, pp 763-767, 1989.
 19. **Sieber F**: Photosensitizing agents for marrow purging in autologous bone marrow transplantation. In *Experimental Hematology Today-1989*. NC Gorin and L Douay, eds. Springer-Verlag, New York, pp 10-15, 1990.
 20. O'Brien JM and **Sieber F**: Merocyanine 540-sensitized photoinactivation of enveloped viruses and its application in the sterilization of blood products. In *Experimental Hematology Today-1989*. NC Gorin and L Douay, eds. Springer-Verlag, New York, pp 26-30, 1990.
 21. **Sieber F**: Photodynamic therapy and bone marrow transplantation. In *Future Directions and Applications in Photodynamic Therapy*. CJ Gomer, ed. SPIE Optical Engineering Press, Bellingham, pp 209-218, 1990.
 22. **Sieber F**: Extracorporeal purging of bone marrow grafts by dye-sensitized photoirradiation. In *Bone Marrow Processing and Purging: A Practical Guide*. A P Gee, ed. CRC Press, Boca Raton, pp 263-280, 1991.
 23. Günther WHH, Searle R and **Sieber F**: Structure-activity relationships in the antiviral and antileukemic photoproperties of merocyanine dyes. *Sem Hematol* 29:88-94, 1992.
 24. **Sieber F**, O'Brien JM and Gaffney DK: Merocyanine-sensitized photoinactivation of enveloped viruses. *Blood Cells* 18:117-128, 1992.
 25. **Sieber F**, O'Brien JM and Gaffney DK: Antiviral effects of photosensitizing merocyanine dyes: Implications for transfusion and bone marrow transplantation. *Sem Hematol* 29:79-87, 1992.
 26. Günther WHH, Searle R and Sieber F: Photosensitizing merocyanine dyes based on selenobarbituric acid. *Phosphorus Sulfur and Silicon* 67:417-424, 1992.

27. **Sieber F**: Phototherapy, photochemotherapy and bone marrow transplantation. *J Hematotherapy* 2:43-62, 1993.
28. **Sieber F**, Gaffney DK, Yamazaki T and Qiu K: Importance of cellular defense mechanisms in the photodynamic purging of autologous bone marrow grafts. In *Advances In Bone Marrow Purging and Processing: Fourth International Symposium*, S Gross, AP Gee and D Worthington-White, eds. Wiley-Liss, New York, pp 147-154, 1994.
29. **Sieber F**: Extracorporeal photochemotherapy. In *Space Technology and Applications International Forum*, MS El-Genk, ed, American Institute of Physics Conference Proceedings 361, Woodbury, NY, pp 413-419, 1996.
30. **Sieber F**: Second-generation merocyanine photosensitizers for photodynamic therapy. *Trends in Photochemistry and Photobiology* 10:1-13, 2003.
31. **Sieber F**, Daziano J-P, Günther WHH, Krieg M, Miyagi K, Sampson RW, Ostrowski MD, Anderson GS, Tsujino I and Bula RJ: Elemental selenium generated by the photobleaching of selenomerocyanine photosensitizers forms conjugates with serum macromolecules that are toxic to tumor cells. *Phosphorus Sulfur, and Silicon and the Related Elements* 180:647-657, 2005.
32. **Sieber F**, Daziano J-P, Sampson RW, Tsujino I, Miyagi K, Ostrowski MD, Anderson GS, Günther WHH and Krieg M: Role of photoproducts in the cytotoxic action of selenomerocyanine-mediated photodynamic therapy. In *Optical Methods for Tumor Treatment and detection: Mechanisms and techniques in Photodynamic Therapy XIV*. D Kessel, ed. Proceedings of SPIE Vol 5689. The International Society for Optical Engineering, Bellingham, pp 56-65, 2005.

Editorials, Letters to Editor, Other

1. **Sieber F**: Biochemie und Entwicklungsbiologie von Octanoldehydrogenase in *Drosophila melanogaster*. Diplomarbeit. Eidgenössische Technische Hochschule, Zürich, 1971.
2. **Sieber F**: Erythropoietin und seine Wirkung auf erythropoietische Zellen. Dissertation Nr. 5678. Eidgenössische Technische Hochschule, Zürich, 1976.
3. Deeg HJ, **Sieber F** and Porcellini A: Introduction: Photomedicine - to use the power of light. *Semin Hematol* 29:77-78, 1992.
4. **Sieber F**: Inactivating enveloped viruses with a merocyanine dye. US Patent Number 4,775,625, issued on October 4, 1988. Licensed to Extracorporeal (Johnson & Johnson).
5. **Sieber F**: Antiviral method, agents and apparatus. US Patent Number 4,915,683, issued on April 10, 1990. Licensed to Extracorporeal (Johnson & Johnson).
6. **Sieber F** and Smith OM: Antiprotozoan method. US Patent Number 5,039,483, issued on August 13, 1991. Licensed to Cobe/Gambro/Navigant.
7. **Sieber F** and Smith OM: Method of eradicating infectious biological contaminants. US Patent Number 5,304,113, issued on April 19, 1994. Licensed to Cobe/Gambro/Navigant.
8. **Sieber F**, Günther WHH, Daziano J-P, Krieg-Kowald M, Bousbaa J and Bula RJ: Method of making, and the use of cytotoxic agents containing elemental selenium. US Patent Number 7,205,002, issued on April 17, 2007.
9. **Sieber F**, Günther WHH, Daziano J-P, Krieg-Kowald M, Bousbaa J and Bula RJ: Method of making, and the use of cytotoxic agents containing elemental selenium. Patent Cooperation Treaty US 03/35125, pending.

Abstracts

1. **Sieber F**, Iscove NN and Winterhalter KH: Separation of human urinary erythropoietin from glycoproteins of similar size using concanavalin A-Sepharose. *Experientia* 29:758, 1973.
2. Iscove NN and **Sieber F**: Macroscopic erythroid colony formation in cultures of mouse bone marrow cells. *Exp Hematol* 2:278, 1974.
3. **Sieber F**: Effects of sialidase and DMSO on erythroid colony growth in culture. *Experientia* 31:748, 1975.
4. **Sieber F**, Iscove NN and Guilbert LJ: Erythropoietin dependence of primitive and late red cell precursors in culture. *Experientia* 32:812, 1976.
5. **Sieber F**, Guilbert LJ and Iscove NN: Purification of erythropoietin: affinity chromatography on insolubilized phytohemagglutinin. *Fed Proc* 35:1627, 1976.
6. Schmell E, Kuhlenschmidt M, **Sieber F** and Roseman S: Stimulation of hepatocyte adhesion by plasma membranes (a new assay). *Fed Proc* 37:1501, 1978.
7. Sieber-Blum M, **Sieber F**, Yamada KM and Cohen AM: Cell surface fibronectin (FN) in cultures of

- differentiating neural crest cells. *J Cell Biol* 79:31a, 1978.
8. **Sieber F** and Roseman S: Assay of intercellular adhesive specificity in transformed and mutant cell lines. *Experientia* 35:979, 1979.
 9. **Sieber F**, Sieber-Blum M and Roseman S: Quantitative analysis of intercellular adhesion in embryonic chick muscle. *J Cell Biol* 83:60a, 1979.
 10. **Sieber F**, Sharkis SJ and Spivak JL: Characterization of anti-theta sensitive regulatory cells (TSRC) by surface charge using the fluorescence activated cell sor-ter. *Exp Hematol* 8:S7, 62, 1980.
 11. Sensenbrenner LL, Sharkis SJ, Spivak LL, **Sieber F** and Stuart RK: Isolation of erythroid progenitor cells from bone marrow using fluoresceinated wheat germ agglutinin. *Exp Hematol* 8:S7, 128, 1980.
 12. **Sieber F** and Spivak JL: Differential sensitivity of mouse hematopoietic progenitor cells to merocyanine 540. *Europ J Cell Biol* 22:416, 1980.
 13. Sieber-Blum M and **Sieber F**: Tumor-promoting phorbol ester affects neural crest cell development. *Europ J Cell Biol* 22:407, 1980.
 14. **Sieber F**, Stuart RK and Spivak JL: Dual effect of tumor-promoting phorbol es-ters on mouse hematopoietic progenitor cells. *J Cell Biol* 87:18a, 1980.
 15. Sieber-Blum M, **Sieber F** and Yamada KM: Adrenergic differentiation of neural crest cells is promoted by cellular fibronectin (CFN). *J Cell Biol* 87:13a, 1980.
 16. Meagher RC, **Sieber F** and Spivak JL: Suppression of hematopoietic progenitor cells by ethanol and acetaldehyde. *Exp Hematol* 9:S9, 137, 1981.
 17. **Sieber F**, Meagher RC, Sensenbrenner LL, Sharkis SJ and Spivak JL: Susceptibility to merocyanine 540-mediated photolysis as a differentiation marker in murine and human hematopoietic stem cells. *Exp Hematol* 9:S9, 149, 1981.
 18. Meagher RC, **Sieber F** and Spivak JL: Preferential suppression of erythroid progenitor cells by ethanol and acetaldehyde. *Clin Res* 29:A340, 1981.
 19. **Sieber F**, Stuart RK, Sensenbrenner LL and Sharkis SJ: Susceptibility to merocyanine 540-mediated photolysis as a differentiation marker in human hematopoietic stem cells. *Blood* 58:102a, 1981.
 20. Dover GJ, Chan T and **Sieber F**: Both early and late erythroid progenitors produce increased levels of HbF in culture. *Blood* 58:67a, 1981.
 21. Meagher RC, **Sieber F** and Spivak JL: Preferential suppression of human erythroid colony formation by ethanol. *Blood* 58:99a, 1981.
 22. Meagher RC, **Sieber F** and Spivak JL: Interaction of mouse marrow macrophages with early with early and late erythroid progenitor cells. *Clin Res* 30:324A, 1982.
 23. **Sieber F**, Stuart RK, Sensenbrenner LL, Sharkis SJ and Spivak JL: Merocyanine 540-mediated photosensitization preferentially inhibits in vitro colony formation by two leukemia cell lines. *Clin Res* 30:331A, 1982.
 24. LaRussa VF, **Sieber F**, Sensenbrenner LL and Sharkis SJ: The effect of neuraminidase on hematopoietic stem cells (CFU-s, BFU-e, CFU-e, and CFU-c) and /or thymic regulatory cells. *Exp Hematol* 10:S11, 59, 1982.
 25. Meagher RC, **Sieber F** and Spivak JL: A differentiation marker for normal murine hematopoietic progenitor cells. *Exp Hematol* 10:S11, 60, 1982.
 26. **Sieber F**, Stuart RK, Sensenbrenner LL, Sharkis SJ and Spivak JL: Plasma membrane properties of normal human hematopoietic progenitor cells and leukemia cells. *Exp Hematol* 10:S11, 85, 1982.
 27. Dover GJ, Chan T and **Sieber F**: Both early and late erythroid progenitors produce increased levels of HbF in culture. *Exp Hematol* 10:S11, 163, 1982.
 28. Sieber-Blum M and **Sieber F**: Plasma membrane heterogeneity in early avian neural crest cells. *J Cell Biol* 95:43a, 1982.
 29. **Sieber F**, Meagher RC, Sutcliffe AM and Spivak JL: Purging of leukemic cells from bone marrow grafts by merocyanine 540-mediated photosensitization. *Clin Res* 31:412A, 1983.
 30. Meagher RC, Levine RF, Spivak JL and **Sieber F**: Effect of ethanol on megakaryocyte progenitor cells and mature megakaryocytes. *Clin Res* 31:319A, 1983.
 31. **Sieber F**, Sharkis SJ and Sieber-Blum M: Modulation of erythropoiesis by thymo-cytes: Effects of the culture system. *Exp Hematol* 11:S14, 29, 1983.
 32. Sharkis SJ, **Sieber F** and Sensenbrenner LL: Cellular interactions which regulate the growth of erythroid progenitor cells in vitro. *Exp Hematol* 11:S14, 27, 1983.
 33. LaRussa VF, **Sieber F**, Sensenbrenner LL and Sharkis SJ: In vivo effects of neuraminidase on the regulation of erythropoiesis. *Exp Hematol* 11:S14, 25, 1983.

34. **Sieber F**, Sharkis SJ and Sieber-Blum M: Does modulation of erythropoiesis by thymocytes depend on an adhesive substrate? *Blood* 62:127a, 1983.
35. **Sieber F**, Hilton J and Colvin OM: Photodynamic therapy of drug-resistant tumors. *Exp Hematol* 12:423, 1984.
36. **Sieber F** and Sieber-Blum M: Cell surface analysis in multilineage systems. *J. Embryo. Exp Morphol* 82:234, 1984.
37. Id J, Spivak JL, **Sieber F** and Noe D: An intracellular mitogen in polycythemia vera and idiopathic myelofibrosis. *Clin Res* 32:697A, 1984.
38. **Sieber F** and Sieber-Blum M: Purging of neuroblastoma cells from bone marrow grafts. *Clin Res* 33:458A, 1985.
39. **Sieber F**: Extracorporeal purging of leukemia and solid tumor cells by merocyanine 540. *Int J Cell Cloning* 3:233-234, 1985.
40. Manna A and **Sieber F**: Cell-cycle specificity of merocyanine 540-mediated photosensitization. *Int J Cell Cloning* 3:277-278, 1985.
41. **Sieber F**, Rao S, Rowley SD and Sieber-Blum M: Selective photosensitization on human neuroblastoma cells: Implications for autologous bone marrow transplantation. *Blood* 66:271a, 1985.
42. **Sieber F**: Dye-mediated photolysis of tumor cells: Implications for autologous bone marrow transplantation. *J Cell Biochem S10D*:220, 1986.
43. **Sieber F**: Elimination of residual tumor cells from autologous bone marrow grafts by dye-mediated photolysis: Preclinical data. *Photochem Photobiol* 43:106S, 1986.
44. Kalyanaraman B and **Sieber F**: On the mechanism of merocyanine 540-mediated photosensitization. *Photochem Photobiol* 43:28S, 1986.
45. **Sieber F**, Craig A, Krueger GJ, Smith RE and Ash RC: Auto-transplantation of bone marrow after extracorporeal purging with merocyanine 540 and light. *Blood* 68:292a, 1986.
46. **Sieber F**: Dye-mediated photosensitization of residual tumor cells. *Leukemia* 1:248, 1987.
47. Krueger GJ, Schober SL and **Sieber F**: Inactivation of solid tumor cells by merocyanine 540-mediated photolysis. *Photochem Photobiol* 45:101S, 1987.
48. Itoh T, Krueger GJ, Messner HA, Jamal N, Tweeddale M and **Sieber F**: Merocyanine 540-mediated photolysis of high grade non-Hodgkin's lymphoma cells. *Blood* 70:320a, 1987.
49. O'Brien JM, Schober SL, Burns WH, Krueger GJ, Montgomery RR and **Sieber F**: Inactivation of enveloped human pathogenic viruses by merocyanine 540-mediated photosensitization and its potential use in blood product sterilization. *Blood* 70:333a, 1987.
50. **Sieber F**: Detection and treatment of minimal residual disease. *Leukemia* 2:190, 1988.
51. O'Brien JM and **Sieber F**: Mutagenicity of merocyanine 540-mediated photosensitization. *Leukemia* 2:195, 1988.
52. Gaffney D and **Sieber F**: Antineoplastic effects of merocyanine 540: Role of serum and serum components. *Proc Amer Assoc Cancer Res* 29: 497, 1988.
53. Itoh T, Ball ED and **Sieber F**: Inactivation of leukemia cells by sequential exposure to merocyanine 540 and cytotoxic antibodies. *J Cell Biochem* 12C:120, 1988.
54. Gaffney DK and **Sieber F**: Mechanistic aspects of merocyanine 540-mediated photolysis. Abstract Book, P-6, MD-PhD Conference, Aspen CO, July 22-25, 1988.
55. Kornguth S, **Sieber F** and Kalinke T: Photolytic effect of polylysylphthalocyanine derivatives on murine Neuro 2a neuroblastoma cells. Abstracts, 18th Annual Meeting of the Society for Neuroscience 14 (2): 1264, 1988.
56. Itoh T, Gaffney D and **Sieber F**: Ex vivo purging of bone marrow with merocyanine 540: Split addition of photosensitizer reduces toxicity to normal stem cells. *Blood* 72: 392a, 1988.
57. Martin LS, Krueger GJ, Orloff SL and **Sieber F**: Dye-mediated photolysis of HIV-1 and HIV-infected cells. *J Cell Biochem S13B*:282, 1989.
58. Gaffney DK and **Sieber F**: Binding of merocyanine 540 by cells labelled with anthroxyloxy fatty acids. *Photochem Photobiol* 49:31S, 1989.
59. Gaffney DK and **Sieber F**: Role of thiols in the merocyanine 540-sensitized photoinactivation of L1210 leukemia cells. Abstract Book, Workshop on Photodynamic Therapy, Boston, MA, June 29-30, 1989.
60. Smith OM and **Sieber F**: Partitioning of tumor cells differing in their susceptibility to merocyanine-mediated photoinactivation. *Photochem Photobiol* 49:31S, 1989.
61. **Sieber F**: Photosensitizing agents for marrow purging in autologous bone marrow transplantation. *Exp Hematol* 17:481, 1989.

62. O'Brien JM and **Sieber F**: Merocyanine 540-sensitized photoinactivation of enveloped viruses and its application in the sterilization of blood products. *Exp Hematol* 17:659, 1989.
63. O'Brien JM, Gaffney DK and **Sieber F**: Sterilization of blood products by merocyanine 540-sensitized photoirradiation: integrity of red cells and mechanism of action. *Blood* 74:295a, 1989.
64. Gaffney DK, Anderson MS, Traul DL and **Sieber F**: Merocyanine 540-sensitized photoinactivation of L1210 leukemia cells: inhibition of transport systems. *J Cell Biochem* 14A:319, 1990.
65. **Sieber F**, O'Brien JM and Gaffney DK: Sterilization of blood products by dye-sensitized photoirradiation. *Photochem Photobiol* 51:96S, 1990.
66. Gaffney DK, Feix JB, Schwarz HP and **Sieber F**: Effects of lipid modulation on the merocyanine 540-sensitized photoinactivation of L1210 leukemia cells. *Photochem Photobiol* 51:66S, 1990.
67. Gaffney DK, O'Brien JM and **Sieber F**: Merocyanine 540-sensitized photoinactivation of leukemia cells and enveloped viruses: mechanisms of action. Abstract Book, 3rd Biennial Meeting of the International Photodynamic Association, Buffalo, NY, July 17-21, p 17, 1990.
68. Smith OM, Traul DL, McOlash L and **Sieber F**: Evaluation of merocyanine 540-sensitized photoirradiation as a method for purging malarially-infected cells from donor blood. *Photochem Photobiol* 51:67S, 1990.
69. Lum LG, Yamagami M, Giddings BR, Schober SL and **Sieber F**: Merocyanine 540 and light inhibits T and B cell functions. *Exp Hematol* 18:560, 1990.
70. Yamagami M, Smith OM, **Sieber F** and Lum LG: Inhibition of T cell activation by merocyanine 540 (MC 540)-mediated photolysis. *Exp Hematol* 18:559, 1990.
71. **Sieber F**, O'Brien JM, Traul DL, Gaffney DK and Smith OM: Potential applications of the photosensitizer, merocyanine 540, in bone marrow transplantation. *Exp Hematol* 18:714, 1990.
72. O'Brien J, Gaffney DK and **Sieber F**: Modulation by thiols of the antiviral and cytotoxic effects of merocyanine 540-sensitized photoirradiation. *Blood* 76:405a, 1990.
73. O'Brien JM, Singh RJ, Feix JB, Kalyanaraman B and **Sieber F**: Action spectra of the antileukemic and antiviral activities of merocyanine 540. *Blood* 76:558a, 1990.
74. Smith OM, Traul DL and **Sieber F**: Functional integrity of human neutrophils after merocyanine 540-sensitized photoirradiation. *J Cell Biochem* 15G:40, 1991.
75. Traul DL, McOlash L, Shih C-Y and **Sieber F**: Merocyanine 540-sensitized photoirradiation for the prophylaxis of graft-versus-host disease? *J Cell Biochem* 15G:41, 1991.
76. Qiu K, Kania D and **Sieber F**: Merocyanine 540-sensitized photoinactivation of leukemia cells. Effects of dose fractionation. *Proc Amer Assoc Cancer Res* 32:389, 1991.
77. Kubo Y and **Sieber F**: Effects of merocyanine 540-sensitized photoirradiation on cells of the hematopoietic microenvironment. *Exp Hematol* 19:567, 1991.
78. **Sieber F**, Gaffney DK, O'Brien JM, Sprague WS, Smith OM, Qiu K, Kania D and Kroes RA: Cellular defense mechanisms against merocyanine 540-mediated photo-dynamic damages. *Exp Hematol* 19:565, 1991.
79. **Sieber F**, O'Brien JM and Gaffney DK: Inactivation of enveloped viruses by merocyanine 540-sensitized irradiation. *Photochem Photobiol* 53 (Supplement):55S-56S, 1991.
80. **Sieber F**: Merocyanine 540: Mechanism of action and potential applications in bone marrow transplantation and blood banking. Abstract Book, Fourth Congress of the European Society for Photobiology, Amsterdam, The Netherlands, September 1-6, p 19, 1991.
81. Whelan HT, Segura A, Przybylski C, Traul D and **Sieber F**: Interactions of merocyanine 540 with human brain tumor cells: preferential binding in vivo and dye-sensitized photoinactivation in vitro. *Ann Neurol* 30:459, 1991.
82. **Sieber F**, Günther WHH, Searle R, O'Brien JM and Gaffney DK: Photosensitizing merocyanine dyes: Structure-activity relationships, Mechanisms of action, and preclinical evaluation as blood sterilizing agents. *Photochem Photobiol* 55S:114-115, 1992.
83. **Sieber F**, Günther WHH, Searle R, O'Brien JM and Gaffney DK: Merocyanine dyes as antiviral agents. Abstract # 107, Abstract Book, 24th Central Regional Meeting, American Chemical Society, Cincinnati, OH, May 26-29, 1992.
84. Traul DL, Smith OM and **Sieber F**: Effects of merocyanine 540-sensitized photoirradiation on cation homeostasis in L1210 leukemia and A549 lung carcinoma cells. *Exp Hematol* 20: 730, 1992.
85. Traul DL and **Sieber F**: Merocyanine 540-sensitized photoirradiation induces apoptosis in HL-60 leukemia cells. *Blood* 80:143a, 1992.
86. **Sieber F**, Günther WHH, Searle R, O'Brien JM, Gaffney DK, Traul DL, Schober SL, Potter D, Bilitz JM and

- Krieg M: Photosensitizing merocyanine dyes with antiviral and antineoplastic activity: Structure-activity relationships and photo-chemical and photophysical characterization. *Photochem Photobiol* 57:66S, 1993.
87. **Sieber F**, Gaffney DK, Yamazaki T and Qiu K: Role of cellular defense mechanisms in the photodynamic purging of autologous bone marrow grafts. Abstract Book, Fourth International Symposium on Bone Marrow Purging and Processing, Orlando, FL, September 16-17, 1993.
 88. Yamazaki T and **Sieber F.**: Effects of temperature on the merocyanine 540-sensitized photoinactivation of leukemia and lymphoma cells. *Blood* 82:655a, 1993.
 89. Yamazaki T and **Sieber F**: Role of cytoprotective mechanisms in the merocyanine 540-sensitized photoinactivation of leukemia and normal hematopoietic stem cells. *Proc Amer Assoc Cancer Res* 35:644, 1994.
 90. Traul DL and **Sieber F**: Induction of apoptosis and necrosis in leukemia and solid tumor cells by merocyanine 540-mediated PDT. *Photochem Photobiol* 59:70S, 1994.
 91. Traul DL, Bilitz JM, Hilliard M Krieg M and **Sieber F**: Modulation of Merocyanine 540-mediated PDT by salicylate and related drugs. *Photochem Photobiol* 59:72S, 1994.
 92. Yamazaki, T. and Sieber, F.: Alkyl-lysophospholipid synergistically enhances the merocyanine 540-mediated purging of leukemia cells from simulated autologous remission marrow grafts. *Blood* 84:497a, 1994.
 93. Krieg M, Bilitz JM, Traul DL and **Sieber F**: Photosensitizing oxonol dyes with antileukemic activity. *Blood* 84:729a, 1994.
 94. Krieg M, Bilitz JM and **Sieber F**: Synthesis and preclinical evaluation of photo-sensitizing oxonol dyes. *Photochem Photobiol* 61:69S, 1995.
 95. Sato Y and **Sieber F**: Ethacrynic acid enhances the merocyanine 540-mediated purging of leukemia cells from autologous bone marrow grafts. *Blood* 86:235a, 1995.
 96. Anderson GS, Gaffney DK, Bilitz JM, O'Brien JM, Krieg M, Günther WHH, Searle R and **Sieber F**: Photosensitizing merocyanine dyes with antileukemic activity: Superior performance of naphth[2,1-d] and selenobarbituric acid derivatives under high serum conditions. *Blood* 86:521a, 1995.
 97. Anderson GS, Gaffney DK, Bilitz JM, O'Brien JM, Krieg M, Günther WHH, Searle R and **Sieber F**: Binding, aggregation, and stability of merocyanine photosensitizers with improved antileukemic activity. *Photochem Photobiol* 63:93S, 1996.
 98. Mangan KF, Mullaney MT and **Sieber F**: Amifostine protects progenitor cell growth and enhances breast cancer cell death in the photolytic merocyanine purging system. Abstract Book "Novel Approaches in Blood and Marrow Transplantation", San Diego, CA, October 2-6, 1996, p 27.
 99. Sato Y and **Sieber F**: Inhibition of aminophospholipid translocation enhances the merocyanine 540-mediated photoinactivation of leukemia cells. *Blood* 88:251b, 1996.
 100. Anderson GS, Günther WHH, Searle R, Bilitz JM, Krieg M and **Sieber F**: Photo-sensitizing merocyanine dyes with antineoplastic activity: Structural requirements for resistance to degradation by plasma. *Blood* 88:147b, 1996.
 101. Sato Y and **Sieber F**: Merocyanine 540-mediated photodynamic therapy inhibits phosphatidylserine translocation in leukemia cells. *Proc Amer Assoc Cancer Res* 38:377, 1997.
 102. Daziano JP, Krieg M and **Sieber F**: Potential involvement of cytotoxic photoproduct in MC54-mediated photoinactivation of leukemia cells. *Photochem Photobiol* 65:59S-60S, 1997.
 103. **Sieber F**: Photochemical purging of autologous hematopoietic stem cells: Les-sons from (and for) phase I/II clinical trials. *Photochem Photobiol* 65:79S-80S, 1997.
 104. Jones LR and **Sieber F**: Light-dependent and light-independent uptake of merocyanine 540 in leukemia cells. *Photochem Photobiol* 65:8S-9S, 1997.
 105. Mangan KF, Mullaney MT and **Sieber F**: Amifostine protects CD34+ purified stem cells in the merocyanine photolytic purging system. *Blood* 90:374a, 1997.
 106. Anderson GS and **Sieber F**: Combination purging with merocyanine 540 and the alkyllysophospholipid, Et-18-OCH₃: synergistic enhancement of the inactivation of solid tumor cells. *Blood* 90:349b, 1997.
 107. Daziano JP, Anderson GS, Günther WHH, Searle R, Krieg M and **Sieber F**: Improved probes and simplified procedures for the quantitative assay of apoptotic cells under high-throughput conditions. *Cytometry* S9:114, 1998
 108. **Sieber F** and Yamazaki T: Importance of cellular defense mechanisms in stem cell purging. *J Hematother* 7:286, 1998.
 109. Anderson GS and **Sieber F**: Combination purging of pediatric solid tumors with Merocyanine 540 and ET-18-OCH₃. *J Hematother*, 7:286, 1998.

110. Daziano JP, Anderson GS, Günther WHH, Tsujino I, Krieg M, Searle R and **Sieber F**: Photoproductalbumin adducts: a new class of antineoplastic agents. *Exp Hematol* 26:787, 1998.
111. Anderson GS and **Sieber F**: Combination purging of autologous stem cell grafts contaminated with solid tumor cells. Abstract Book, Annual Meeting of The American Society of Pediatric Hematology/Oncology, Chicago, IL, Sept 10-12, 1998, p 38.
112. Tsujino I, Anderson GS and **Sieber F**: Hyperthermia preferentially potentiates the Merocyanine 540-mediated photoinactivation of small cell lung carcinoma cells. *Blood* 92:319b, 1998.
113. Tsujino I and **Sieber F**: Selective enhancement of the antitumor effect of merocyanine 540-PDT by amphotericin B used in combination with amifostine. *Photochem Photobiol* 69: 37S, 1999.
114. **Sieber F**, Anderson GS and Tsujino I: Photochemical purging of stem cell grafts contaminated with solid tumor cells. *Exp Hematol* 27:128, 1999.
115. **Sieber F**, Daziano J-P, Tsujino I, Anderson G and Krieg M: Antileukemic activity of photoproduct-albumin adducts. Late-Braking Abstracts, LBA016, 28th Annual Meeting of The International Society for Experimental Hematology, Monte Carlo, Monaco, July 10-14, 1999.
116. Indig GL, Anderson GS, Nichols MG, Bartlett JA, Mellon WS and **Sieber F**: Triarylmethane dyes as therapeutic agents for the photochemical purging of auto-logous bone marrow grafts from residual tumor cells. *Biophys J* 78:256a, 2000.
117. Tsujino I, Bousbaa J and **Sieber F**: Albumin uptake defines sensitivity to selenomerocyanine-derived photoproduct-albumin adducts. *Proc Amer Assoc Cancer Res* 41:700, 2000.
118. Tsujino I and **Sieber F**: Genetic variability in the response of normal murine hematopoietic progenitor cells to photochemical purging. Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH), Tampa, FL, July 8-11, 2000, Onsite Guide, pp 54-55, 2000.
119. Daziano J-P, Bousbaa J, Tsujino I, Anderson GS, Günther WHH, Krieg M and **Sieber F**: Preferential targeting of tumor cells with selenomerocyanine-derived photoproduct-albumin adducts. *Europ J Cell Biol* 79 (S52): 178, 2000.
120. Miyagi K, Bousbaa J and **Sieber F**: Low-dose Merocyanine 540-PDT potentiates the anti-tumor effect of crystal violet-PDT. Program and Abstract Book, 29th Annual Meeting of the American Society for Photobiology, Chicago, IL, July 7-12, 2001, p 38, 2001.
121. Miyagi K and **Sieber F**: Triarylmethane dyes and Merocyanine 540 for the ex vivo purging of hematopoietic stem cells. *Proc Amer Assoc Cancer Res* 43: 650, 2002.
122. Miyagi K and **Sieber F**: Response of leukemia cells, solid tumor cells, drug-resistant tumor cells and normal hematopoietic progenitor cells to crystal violet and Merocyanine 540-PDT. Program and Abstracts, 30th Annual Meeting of the American Society for Photobiology, Quebec City, Canada, July 13-17, 2002, pp 104-105, 2002.
123. **Sieber F**, Daziano J-P, Anderson GS, Miyagi K, Sampson RW, Tsujino I, Günther WHH, Krieg M, Bousbaa J and Försterling FH: Colloidal selenium generated by photobleaching of selenomerocyanine dyes combines with serum macromolecules to form conjugates that are preferentially cytotoxic to leukemia and selected solid tumor cells. *Blood* 100: 224b, 2002.
124. Miyagi K, Sampson RW, Tsujino I, Günther WHH, Krieg M and **Sieber F**: Proteinated subnanoparticles of elemental selenium potentiate the anti-tumor effect of ionizing radiation and selected chemotherapeutic agents. *Proc Amer Assoc Cancer Res* 44: 385, 2003.
125. **Sieber F**: Proteinated subnanoparticles of colloidal selenium: A new class of anti-leukemia/lymphoma agents. *Leukemia* 17: 683, 2003.
126. **Sieber F**: Selenium in oxidation state zero is a potent and selective anti-leukemia/lymphoma agent. *Exp Hematol* 31 (S1):119-120, 2003.
127. **Sieber F**, Daziano J-P, Günther WHH, Krieg M, Miyagi K, Sampson RW, Ostrowski MD, Anderson GS, Tsujino I and Bula R: Elemental selenium generated by the photobleaching of selenomerocyanine photosensitizers forms conjugates with serum macromolecules that are toxic to tumor cells. Abstract Book, 9th International Conference on the Chemistry of Selenium and Tellurium (ICCST-9), Bombay, India, February 23-27, 2004, p 1, 2004.
128. Tsujino I, Miyagi K, Sampson RW, Günther WHH, Krieg M and **Sieber F**: Proteinated elemental selenium potentiates the anti-tumor effect of ionizing radiation and chemotherapeutic agents and is only minimally affected by drug resistance mechanisms. *Blood* 104:175b, 2004.
129. **Sieber F**, Daziano J-P, Sampson RW, Tsujino I, Miyagi K, Ostrowski M, Anderson GS, Günther WHH and Krieg M: Role of photoproducts in the cytotoxic action of selenomerocyanine-mediated PDT. Abstract Book, Photonics West, BiOS 2005, Optical Methods for Tumor Treatment and Detection: Mechanisms

- and Techniques in Photodynamic Therapy, San Jose, CA, January 22-23, 2005, Abstract No. 5689-13, 2005.
130. **Sieber F**, Daziano J-P, Tsujino I, Miyagi K, Sampson RW, Anderson GS, Ostrowski MD, Gunther WHH and Krieg M: Proteinated elemental selenium; A novel class of anti-cancer agents. Abstract Book, International Conference on Tumor Progression and Therapeutic Resistance, Philadelphia, PA, November 8-9, 2004, p 80, 2004.
 131. Sampson RW, Miyagi K, Ostrowski MD, Günther WHHG, Krieg M and **Sieber F**: Elemental selenium for the treatment of breast cancer. Proceedings, Era of Hope Department of Defense Breast Cancer Research Program Meeting, Philadelphia, June 8-11, 2005, p 298.
 132. Daziano JP, Gunther WHH, Krieg M, Miyagi K, Sampson RW, Ostrowski MD, Anderson GS, Tsujino I, Bula RJ and **Sieber F**: Elemental selenium generated by photobleaching of selone photosensitizers forms conjugates with serum proteins that are selectively cytotoxic to tumor cells. Abstract Book, Selenium 2006 - 8th International Symposium on Selenium in Biology and Medicine, Madison, WI, July 25-30, 2006, p 51, 2006.
 133. **Sieber F**: Photochemical inactivation of residual tumor cells in autologous hematopoietic stem cell grafts. Abstract Book, 11th World Congress of the International Photodynamic Association, Shanghai (China), March 28-31, 2007.
 134. **Sieber F**, Muir SA, Sampson RW and Gopal VM: Interactions of cytotoxic selenium-protein conjugates with standard chemotherapy drugs: quantitative analysis by the combination index method. Abstract Book, Era-Of-Hope Department of Defense Breast Cancer Research Program Meeting, Baltimore, MD, June 25-28, 2008, p 125, 2008.
 135. **Sieber F**, Muir SA, Cohen EP, North PE, Fish BL, Irving AA, Mader M and Moulder JE: High-dose selenium for the mitigation of radiation injury: a pilot study in a rat model. Abstract Book, 54th Annual Meeting of the Radiation Research Society, Boston, MA, September 21-24, 2008, p 96, 2008.
 136. **Sieber F**, Muir SA, Cohen EP, Fish BL, Mäder M, Schock AM, Althouse BJ, and Moulder JE: Dietary selenium (Se) for the mitigation of radiation injury: effects of dose escalation. Abstract Book, 55th Annual Meeting of the Radiation Research Society, Savannah, GA, October 3-7, 2009, p 142, 2009.
 137. Traul DL, **Sieber F**. Inhibitory effects of merocyanine 540-mediated photodynamic therapy on cellular immune functions: A role in the prophylaxis of graft-versus-host disease? *J Photochem Photobiol B*. 2015 Dec;153:153-63. PMID: PMC4674338
 138. **Sieber F**, Daziano JP, Sampson RW, Tsujino I, Miyagi K, Ostrowski MD, Anderson GS, Günther WHH, Krieg M. Role of photoproducts in the cytotoxic action of selenomerocyanine-mediated photodynamic therapy *Progress in Biomedical Optics and Imaging - Proceedings of SPIE*. 2005;5689:56-65.
 139. Sato Y, Daziano JP, **Sieber F**. Photochemical purging of autologous stem cell grafts potentiation of the antileukemic activity of merocyanine 540 by ethacrynic acid *Cancer Research, Therapy and Control*. 1998;5(4):241-251.
 140. Daziano JP, Anderson OS, Günther WHH, Tsujino I, Krieg M, Searle R, **Sieber F**. Photoproduct-albumin adducts: a new class of antineoplastic agents *Experimental Hematology*. 1998;26(8):786.
 141. Krieg M, Bilitz JM, Traul DL, **Sieber F**. Photosensitizing oxonol dyes with antineoplastic activity *Cancer Research Therapy and Control*. 1995;4(3):163-172.
 142. Qiu Kang , **Sieber F**. Pharmacokinetics of merocyanine 540 *Cancer Research, Therapy and Control*. 1993;3(4):239-243.
 143. Gunther WH, Searle R, **Sieber F**. Photosensitizing merocyanine dyes based on selenobarbituric acid Phosphorus, Sulfur, and Silicon and the Related Elements. 1 April 1992;67(1-4):417-424.
 144. **Sieber F**. Photodynamic therapy and bone marrow transplantation *Proceedings of SPIE - The International Society for Optical Engineering*. 21 July 1990;10306:209-218.
 145. **Sieber F**. Antineoplastic and antiviral properties of merocyanine 540 *Proceedings of SPIE - The International Society for Optical Engineering*. 17 March 1989;997:128-131.
 146. **Sieber F**. A role for photodynamic therapy in autologous bone marrow transplantation *Proceedings of SPIE - The International Society for Optical Engineering*. 19 February 1988;847:148-152.
 147. Sieber-Blum M, **Sieber F**. Plasma membrane heterogeneity in early avian neural crest cells *Journal of Cell Biology*. 1982;95(2 II).
 148. Meagher RC, **Sieber F**, Spivak JL. Suppression of hematopoietic progenitor cells by ethanol and acetaldehyde *Experimental Hematology*. 1981;9(Suppl. 9):137.
 149. **Sieber F**, Spivak JL. Differential sensitivity of mouse hematopoietic progenitor cells to merocyanine 540 *European Journal of Cell Biology*. 1980;22(1).

150. Sieber-Blum M, **Sieber F**. Tumor-promoting phorbol ester affects neural crest cell development *European Journal of Cell Biology*. 1980;22(1).
151. **Sieber F**, Stuart RK, Spivak JL. Dual effect of tumor-promoting phorbol esters on mouse hematopoietic progenitor cells *Journal of Cell Biology*. 1980;87(2 II).
152. **Sieber F**, Iscove NN, Winterhalter KH. Separation of human urinary erythropoietin from glycoproteins of similar size using concanavalin A Sepharose *Experientia*. 1973;29(6):758.
153. Yamazaki T, **Sieber F**. Erratum: The alkyl-lysophospholipid, ET-18-OCH₃ synergistically enhances the Merocyanine 540-mediated photoinactivation of leukemia cells: implications for the extracorporeal purging of autologous hematopoietic stem cells (*Bone Marrow Transplantation*, (1997), 19, 2, (113-119), 10.1038/sj.bmt.1700625) *Bone Marrow Transplantation*. 1 July 1997;20(1):95.
154. Spivak JL, **Sieber F**. ERYTHROPOIETIN Hormones in Normal and Abnormal Human Tissues: Volume 3. 1 January 2019;3:63-96.